Hyperfine, Inc. (HYPR) — SEC Filings
Hyperfine, Inc. (HYPR) — 26 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 15 8-K, 6 10-Q, 2 DEF 14A.
View Hyperfine, Inc. on SEC EDGAR
Overview
Hyperfine, Inc. (HYPR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Hyperfine, Inc. (HYPR) reported a net loss of $11.019 million for the three months ended September 30, 2025, an increase from the $10.326 million net loss in the same period of 2024. Total sales decreased by 5.6% to $3.437 million in Q3 2025 from $3.643 million in Q3 2024, driven by a decline in dev
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 21 neutral. The dominant filing sentiment for Hyperfine, Inc. is neutral.
Filing Type Overview
Hyperfine, Inc. (HYPR) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of HYPR's 23 recent filings, 4 were flagged as high-risk, 10 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3.437M |
| Net Income | -$11.019M |
| EPS | N/A |
| Debt-to-Equity | 0.55 |
| Cash Position | $21.564M |
| Operating Margin | -259.8% |
| Total Assets | $41.511M |
| Total Debt | $14.639M |
Key Executives
- Dr. Jonathan S. B. T. Evelyn
- Dr. David M. Shavelle
Industry Context
Hyperfine operates in the medical imaging technology sector, specifically focusing on point-of-care ultrasound devices. The industry is characterized by rapid technological advancements, increasing demand for portable and AI-enhanced diagnostic tools, and a stringent regulatory environment. Key competitors often include established medical device manufacturers and innovative startups vying for market share through product differentiation and regulatory approvals.
Top Tags
10-Q (4) · financials (3) · regulatory-filing (3) · financial-condition (3) · operations (3) · Medical Devices (2) · AI in Healthcare (2) · Cash Burn (2) · Regulatory Approval (2) · corporate-action (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $11.019M | Increased from $10.326M in Q3 2024 |
| Total Sales (Q3 2025) | $3.437M | Decreased 5.6% from $3.643M in Q3 2024 |
| Cash & Cash Equivalents | $21.564M | As of September 30, 2025, down from $37.645M at Dec 31, 2024 |
| Net Loss (9 Months 2025) | $29.662M | Slightly improved from $30.330M in 9 Months 2024 |
| Total Sales (9 Months 2025) | $8.270M | Decreased from $10.569M in 9 Months 2024 |
| R&D Expenses (Q3 2025) | $4.048M | Decreased from $5.865M in Q3 2024 |
| Warrant Liabilities | $3.497M | New liability as of September 30, 2025 |
| Class A Common Stock Outstanding | 82,113,369 | As of November 3, 2025 |
| SEC File Number | 001-39949 | Identifier for Hyperfine, Inc.'s filings |
| IRS Employer Identification No. | 98-1569027 | Tax identification for Hyperfine, Inc. |
| Net Loss | $18.643M | Six months ended June 30, 2025, improved from $20.004M in prior year. |
| Total Sales | $4.833M | Six months ended June 30, 2025, a 30.2% decrease from $6.926M in prior year. |
| Device Sales | $3.650M | Six months ended June 30, 2025, a 35.7% decrease from $5.674M in prior year. |
| Cash and Cash Equivalents | $25.420M | As of June 30, 2025, down from $37.645M at December 31, 2024. |
| Research and Development Expenses | $9.578M | Six months ended June 30, 2025, decreased from $11.529M in prior year. |
Frequently Asked Questions
What are the latest SEC filings for Hyperfine, Inc. (HYPR)?
Hyperfine, Inc. has 26 recent SEC filings from Feb 2024 to Dec 2025, including 15 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HYPR filings?
Across 26 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 21 neutral. The dominant sentiment is neutral.
Where can I find Hyperfine, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Hyperfine, Inc. (HYPR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Hyperfine, Inc.?
Key financial highlights from Hyperfine, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HYPR?
The investment thesis for HYPR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Hyperfine, Inc.?
Key executives identified across Hyperfine, Inc.'s filings include Dr. Jonathan S. B. T. Evelyn, Dr. David M. Shavelle.
What are the main risk factors for Hyperfine, Inc. stock?
Of HYPR's 23 assessed filings, 4 were flagged high-risk, 10 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Hyperfine, Inc.?
Forward guidance and predictions for Hyperfine, Inc. are extracted from SEC filings as they are enriched.